Microbiome-focused asthma management strategies

Shukla, SD; Shastri, MD; Chong, WC; Dua, K; Budden, KF; Mahmood, MQ; Hansbro, NG; Keely, S; Eri, R; Patel, RP; Peterson, GM; Hansbro, PM

Microbiome-focused asthma management strategies

Shukla, SD Shastri, MD Chong, WC Dua, K

Budden, KF Mahmood, MQ Hansbro, NG Keely, S Eri, R Patel, RP Peterson, GM Hansbro, PM

Permalink

Publication Type:: Journal Article
Citation:: Current Opinion in Pharmacology, 2019, 46 pp. 143 - 149
Issue Date:: 2019-06-01

Closed Access

	Filename	Description	Size
	1-s2.0-S1471489219300025-main.pdf	Published Version	1.01 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Shukla, SD	en_US
dc.contributor.author	Shastri, MD	en_US
dc.contributor.author	Chong, WC	en_US
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159	en_US
dc.contributor.author	Budden, KF	en_US
dc.contributor.author	Mahmood, MQ	en_US
dc.contributor.author	Hansbro, NG	en_US
dc.contributor.author	Keely, S	en_US
dc.contributor.author	Eri, R	en_US
dc.contributor.author	Patel, RP	en_US
dc.contributor.author	Peterson, GM	en_US
dc.contributor.author	Hansbro, PM https://orcid.org/0000-0002-4741-3035	en_US
dc.date.available	2019-06-24	en_US
dc.date.issued	2019-06-01	en_US
dc.identifier.citation	Current Opinion in Pharmacology, 2019, 46 pp. 143 - 149	en_US
dc.identifier.issn	1471-4892	en_US
dc.identifier.uri	http://hdl.handle.net/10453/136096
dc.description.abstract	© 2019 Elsevier Ltd Asthma is a common, heterogeneous and serious disease with high prevalence globally. Poorly controlled, steroid-resistant asthma is particularly important as there are no effective therapies and it exerts substantial healthcare and societal burden. The role of microbiomes, particularly in chronic diseases has generated considerable interest in recent times. Existing evidence clearly demonstrates an association between asthma initiation and the microbiome, both respiratory and gastro-intestinal, although its’ roles are poorly understood when assessing the asthma progression or heterogeneity (i.e. phenotypes/endotypes) across different geographical locations. Moreover, modulating microbiomes could be preventive and/or therapeutic in patients with asthma warrants urgent attention. Here, we review recent advances in assessing the role of microbiomes in asthma and present the challenges associated with the potential therapeutic utility of modifying microbiomes in management.	en_US
dc.relation	http://purl.org/au-research/grants/nhmrc/GNT1079187
dc.relation.ispartof	Current Opinion in Pharmacology	en_US
dc.relation.isbasedon	10.1016/j.coph.2019.06.003	en_US
dc.subject.classification	Pharmacology & Pharmacy	en_US
dc.title	Microbiome-focused asthma management strategies	en_US
dc.type	Journal Article
utslib.citation.volume	46	en_US
utslib.for	1102 Cardiorespiratory Medicine and Haematology	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
utslib.copyright.status	closed_access
pubs.publication-status	Published	en_US
pubs.volume	46	en_US

Abstract:

© 2019 Elsevier Ltd Asthma is a common, heterogeneous and serious disease with high prevalence globally. Poorly controlled, steroid-resistant asthma is particularly important as there are no effective therapies and it exerts substantial healthcare and societal burden. The role of microbiomes, particularly in chronic diseases has generated considerable interest in recent times. Existing evidence clearly demonstrates an association between asthma initiation and the microbiome, both respiratory and gastro-intestinal, although its’ roles are poorly understood when assessing the asthma progression or heterogeneity (i.e. phenotypes/endotypes) across different geographical locations. Moreover, modulating microbiomes could be preventive and/or therapeutic in patients with asthma warrants urgent attention. Here, we review recent advances in assessing the role of microbiomes in asthma and present the challenges associated with the potential therapeutic utility of modifying microbiomes in management.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/136096